LT 3001

Drug Profile

LT 3001

Alternative Names: LT3001

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lumosa Therapeutics
  • Class Antithrombotics; Neuroprotectants; Peptides; Small molecules
  • Mechanism of Action Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Stroke

Most Recent Events

  • 28 Jul 2017 Phase-I clinical trials in Stroke (In volunteers) in USA (unspecified route)
  • 22 Jun 2017 Lumosa Therapeutics approves IND application for LT-3001 in Stroke
  • 22 Jun 2017 Lumosa Therapeutics files an IND application with the US FDA in USA for Stroke prior to June 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top